— BMB proprietary 5-HT2C agonist, BMB-101, shows efficacy in pre-clinical models of Dravet Syndrome/Epilepsy, with lower seizure duration and frequency — — Effect of BMB compounds was consistent with other anti-epileptics such as fenfluramine — Vancouver, BC – August 18, 2021 – Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG)…
Before the pandemic, the world was facing a variety of threats such as climate change, population growth and ageing demographics. In addition, rapid advances in science and technology have been changing how people live, bringing new problems and new solutions. These issues remain, but the focus has understandably shifted to the global pandemic. Before…
The end of the pandemic is in sight. Vaccine rollouts are proving effective, and even with new variants and uneven distribution, COVID-19 is being brought under control. The global economy was severely impacted, and some sectors are still suffering. However, some industries, such as mental health companies, are seeing an unprecedented influx of funding. …
After decades of promising research, fading stigma, and rising need, psychedelic drugs may soon be available to treat pervasive health conditions such as PTSD, depression, and addiction. Over the past few years, a robust business community that includes startups, investors, and even public companies sprung up in an effort to bring drugs like MDMA…
If 2020 taught us anything, it’s that investment dollars will continue to flow, and detecting the direction of the current is the difference between success and failure. It seemed unlikely that we would be on the precipice of a boom in investment volume just a year ago, but that seems to be what we…
When major societal upheavals occur, some sectors suffer while others benefit. The COVID-19 pandemic has shifted goalposts for a lot of industries. Most have suffered, but a few, like the mental health industry, have seen an upsurge in demand. The need for mental health products has been rising for decades, but large pharmaceutical companies…
Vancouver, BC – June 16, 2021 – Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy, and pain, is pleased to announce that it has submitted an application to list on The Nasdaq Stock Market (“Nasdaq”). The Company…
Vancouver, British Columbia –June 14, 2021 – Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”)(CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced a new appointment to its Board of Directors and one addition to its leadership team: Emer Lahey, Ph.D.,…
Vancouver, BC – June 11, 2021 – Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG)(OTCQB:BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced that Ian McDonald, Chief Executive Officer, and Dr. Gideon Shapiro Ph.D, Vice President of Discovery,will be presenting at the H.C. Wainwright…
VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced that Ian McDonald, Chief Executive Officer, and Dr. Gideon Shapiro Ph.D, Vice President of Discovery, will be presenting…
×
"*" indicates required fields